Market Cap (In AUD)
5.03 Million
Revenue (In AUD)
1.21 Million
Net Income (In AUD)
-1.64 Million
Avg. Volume
18.4 Thousand
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.06-0.105
- PE
- -
- EPS
- -
- Beta Value
- 0.41
- ISIN
- AU0000048621
- CUSIP
- Q496BJ108
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Narelle Warren B.Com, B.Com., L.L.B., LLB
- Employee Count
- -
- Website
- https://www.invextherapeutics.com
- Ipo Date
- 2019-07-05
- Details
- Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
More Stocks
-
1289
-
FUND
-
418550JEIO Co., Ltd.
418550
-
INTSTOILInter State Oil Carrier Limited
INTSTOIL
-
KHNGF
-
IMCCIM Cannabis Corp.
IMCC
-
002907
-
MUX